Results 51 to 60 of about 29,283 (270)

Measurement of ctDNA at first evaluation.

, 2016
Evolution of ctDNA concentration (ng/mL) between baseline (T0) and first evaluation (E1) showing a (A) decrease, (B) increase, (C) normalization, or (D) negativity at both time points. (E) PFS according to ctDNA evolution between T0 and E1. (F) Waterfall
Eleonora Zonta (3153192), Audrey Didelot (3153195), Constance Thibault (3603650), Yves Rozenholc (3603653), Elizabeth Fabre (187892), Camille Lours (3603656), Nicolas Pécuchet (3153186), Pierre Combe (3603659), Pierre Laurent-Puig (56604), Laure Gibault (228316), Hélène Blons (187905), Valérie Taly (3153189)   +11 more
core   +1 more source

Lung cancer ctDNA sequencing.

, 2016
Lung cancer ctDNA sequencing.
Melissa M. Pentony (3119964), Avinash Gupta (3119970), Pamela J. Kaisaki (52706), Carme Camps (278092), Anthony Cutts (3119985), Jenny C. Taylor (113518), Denis C. Talbot (3119982), Kulvinder Kaur (18480), Shirley Henderson (3119961), Ioannis Karydis (379289), Anna Schuh (3119973), Suzanne Page (3119976), Mark R. Middleton (3119988), Niko Popitsch (795982), Gareth Wilson (3119967), Dimitris Vavoulis (3119979)   +15 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls

Journal of Laboratory Medicine, 2022
Early detection is crucial for optimal treatment and prognosis of cancer. New approaches for pan-cancer screening comprise the comprehensive characterization of circulating tumor DNA (ctDNA) in plasma by next generation sequencing and molecular profiling
Holdenrieder Stefan, Ungerer Vida, Oberhofer Angela, Bronkhorst Abel Jacobus   +3 more
doaj   +1 more source

Regulatory implications of ctDNA in immuno-oncology for solid tumors

, 2023
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials.
Richard Pazdur, Shenghui Tang, Erik W Bloomquist, Julia A Beaver, Paz J Vellanki, Reena Philip, Harpreet Singh, Anand Pathak, Michael J Fusco, Soma Ghosh   +9 more
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo

Cells, 2019
One of the greatest challenges in neuro-oncology is diagnosis and therapy (theranostics) of leptomeningeal metastasis (LM), brain metastasis (BM) and brain tumors (BT), which are associated with poor prognosis in patients.
Olga A. Sindeeva, Roman A. Verkhovskii, Mustafa Sarimollaoglu, Galina A. Afanaseva, Alexander S. Fedonnikov, Evgeny Yu. Osintsev, Elena N. Kurochkina, Dmitry A. Gorin, Sergey M. Deyev, Vladimir P. Zharov, Ekaterina I. Galanzha   +10 more
doaj   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

ctDNA at tumor progression.

, 2016
(A) Time to RECIST progression and time to ctDNA progression in 47 patients with positive ctDNA at time of progression (ToP). (B) Mutations detected in plasma at baseline (T0) and at time of progression (ToP) (n = 66 patients).
Eleonora Zonta (3153192), Audrey Didelot (3153195), Constance Thibault (3603650), Yves Rozenholc (3603653), Elizabeth Fabre (187892), Camille Lours (3603656), Nicolas Pécuchet (3153186), Pierre Combe (3603659), Pierre Laurent-Puig (56604), Laure Gibault (228316), Hélène Blons (187905), Valérie Taly (3153189)   +11 more
core   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source